Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
Blood Neoplasia · 2026-10 · 100331
DOI: 10.1016/j.bneo.2026.100331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Neoplasia, 2026-10. Verfasst von Brian Koffman und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BeOne Medicines Ltd.
Abstract (Originalsprache)
This retrospective study used data from the US Flatiron Health Research Database to evaluate the impact of genetic testing before first-line (1L) treatment initiation on treatment selection and real-world clinical outcomes in patients with chronic lymphocytic leukemia (CLL). Primary exposure variables included testing before 1L initiation for 17p deletion (del17p), TP5 3, and immunoglobulin heavy variable chain (IGHV) mutations. Among 5481 patients, 83.3% were tested for del17p/ TP53 and 51.9% for IGHV. For no testing versus testing for del17p/ TP53 before 1L treatment, median (95% CI) real-world time to next treatment or death (rwTTNT) was 30.0 (26.5-36.4) versus 41.7 (39.1-44.1) months (adjusted HR [aHR] 1.10; 95% CI 0.99-1.22; P = .093); for IGHV, rwTTNT was 34.0 (31.0-37.8) versus 45.3 (41.6-49.3) months (aHR 1.12; 95% CI 1.03-1.22; P = .007), respectively. Median real-world overall survival (rwOS) was not reached for any group; risk of death was 28% and 27% higher, respectively, with no testing versus testing for del17p/ TP53 ( P = .001) and IGHV ( P .5). This large, real-world study suggests that pre-treatment genetic testing is associated with improved outcomes, emphasizing that checking if appropriate tests were performed before 1L treatment may serve as a proxy for optimal CLL management.
Förderung
- BeOne Medicines Ltd
Zitieren
APA
Koffman, B., Wang, X., Fu, Q., Yuan, D., Beuge, D. V., Brand, K. K., Maglinte, G. A., & Seymour, E. K. (2026). Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia. Blood Neoplasia, 100331. https://doi.org/10.1016/j.bneo.2026.100331
Vancouver
Koffman B, Wang X, Fu Q, Yuan D, Beuge DV, Brand KK, et al. Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia. Blood Neoplasia. 2026:100331. doi:10.1016/j.bneo.2026.100331
BibTeX
@article{Koffman2026,
author = {Koffman, Brian and Wang, Xiaoliang and Fu, Qianhong and Yuan, Dong and Beuge, Derrick van and Brand, Krysten Klein and Maglinte, Gregory A. and Seymour, Erlene K.},
title = {Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia},
journal = {Blood Neoplasia},
year = {2026},
pages = {100331},
doi = {10.1016/j.bneo.2026.100331}
}
EUVIMED